Patents by Inventor Naresh Talwar

Naresh Talwar has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20190076366
    Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.
    Type: Application
    Filed: April 3, 2018
    Publication date: March 14, 2019
    Applicant: Pharmascience, Inc.
    Inventors: Mathew Philip, Naresh Talwar
  • Publication number: 20180117158
    Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.
    Type: Application
    Filed: December 27, 2017
    Publication date: May 3, 2018
    Applicant: Pharmascience Inc.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Publication number: 20170014340
    Abstract: Orally disintegrating medicaments comprising Nabilone allow for improved treatment of nausea arising from chemo therapy for cancer. The medicaments comprise appropriate excipients such that the medicament disintegrates in the mouth in 30 seconds or less, while exhibiting sufficient stability for storage. In a preferred embodiment, the medicament is in the form of a tablet formed from granules. The granules consist of an intra-granular fraction comprising nabilone, mannitol, and polyvinyl pyrrolidone and an extra-granular fraction comprising mannitol, calcium silicate, crospovidone, and magnesium stearate. Processes for manufacturfing such medicaments are also disclosed.
    Type: Application
    Filed: March 4, 2015
    Publication date: January 19, 2017
    Applicant: Pharmascience Inc.
    Inventors: Ousmane Diallo, Mathew Philip, Naresh Talwar
  • Publication number: 20160106680
    Abstract: The present invention relates to an immediate release orally administrable abuse-deterrent pharmaceutical formulation comprising: at least one pharmaceutically active ingredient susceptible to abuse; at least one gelling polymeric compound selected from the group consisting of: polysaccharides, sugars, sugar derived alcohols, starches, starch derivatives, cellulose derivatives, Carrageenan, pectin, sodium alginate, gellan gum, xanthan gum, poloxamer, Carbopol®, PolyOx®, povidone, hydroxypropyl methylcellulose (HPMC), hypermellose, and combinations thereof; at least one disintegrant and optionally at least one surfactant, wherein said formulation exhibit properties related to deterring the abuse, via injection or nasal inhalation when being tampered and exposed to aqueous, alcoholic, acidic and basic media.
    Type: Application
    Filed: May 30, 2014
    Publication date: April 21, 2016
    Applicant: Pharmascience Inc.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Publication number: 20150250886
    Abstract: A modified release orally administrable abuse-deterrent pharmaceutical composition comprising: a therapeutically effective amount of an active pharmaceutical ingredient and konjac glucomannan. The active pharmaceutical ingredient can be selected from a number of compounds but is generally aimed to be a compound which is subject to widespread abuse such as opioids.
    Type: Application
    Filed: September 30, 2013
    Publication date: September 10, 2015
    Applicant: PHARMASCIENCE INC.
    Inventors: Krishna Hari Bhandari, Naresh Talwar
  • Publication number: 20150110869
    Abstract: The present invention relates to an adhesive-free pharmaceutical composition for the treatment of hepatitis B virus infections, comprising at least one guanine-based antiviral active pharmaceutical ingredient. More specifically, the present invention concerns an oral pharmaceutical composition comprising: adhesive-free granules comprising therapeutically effective amount of entecavir and at least one intra-granular pharmaceutically acceptable excipient; at least one extra-granular pharmaceutical excipient, and, optionally, a moisture barrier coating. A method of manufacturing an adhesive-free pharmaceutical composition is also disclosed.
    Type: Application
    Filed: May 28, 2013
    Publication date: April 23, 2015
    Inventors: Mathew Philip, Naresh Talwar
  • Publication number: 20140335176
    Abstract: The present invention relates to a delayed release pharmaceutical composition containing doxylamine succinate and pyridoxine HCl for treatment of nausea and vomiting during pregnancy. More specifically, the present invention concerns a disintegrant-free delayed release pharmaceutical composition for oral administration comprising a core and an enteric coating, wherein said core comprising: a) at least one pharmaceutically active ingredient, and b) at least one pharmaceutically acceptable excipient, wherein said composition provides an in vitro drug release profile of about 80% of active ingredient dissolved within 20 minutes as measured by USP Type II apparatus and also a manufacturing process of said pharmaceutical composition.
    Type: Application
    Filed: December 7, 2012
    Publication date: November 13, 2014
    Inventors: Prashant Monohar Mandaogade, David Ma, Naresh Talwar
  • Publication number: 20100204292
    Abstract: A pharmaceutical composition comprising i) an intra-granular fraction containing a pharmaceutically acceptable active component and a first excipient and ii) an extra-granular fraction containing a second excipient. The pharmaceutical composition is characterized by being substantially surfactant-free and by exhibiting a rapid-dissolution profile.
    Type: Application
    Filed: August 17, 2007
    Publication date: August 12, 2010
    Inventors: Jack Aurora, Naresh Talwar, Jyoti Missra, Kiran Shankar Lagu
  • Publication number: 20090142398
    Abstract: The present invention relates to a stable pharmaceutical composition comprising a pharmaceutically active substance having poor water solubility dispersed in a pharmaceutically acceptable disintegration matrix, said disintegration matrix comprising at least one pharmaceutically acceptable disintegrant, a pharmaceutically acceptable basic agent provided in a molar ratio of basic agent to active substance of 1:1 to 10:1, a water-insoluble pharmaceutically acceptable diluent, optionally, if desired or necessary at least one pharmaceutically acceptable excipients and/or pharmaceutically acceptable adjuvants, and optionally a pharmaceutically acceptable surfactant or emulsifier. The present invention also provides a process to make such.
    Type: Application
    Filed: November 19, 2008
    Publication date: June 4, 2009
    Applicant: Pharmascience Inc.
    Inventors: Mathew Philip, Naresh Talwar, Rasik Patel, Vinayak Pathak
  • Publication number: 20080171083
    Abstract: The present invention relates to controlled or sustained release solid pharmaceutical compositions, to pharmaceutical excipients for use in the manufacture of such compositions and to methods of producing such compositions and excipients. The controlled or sustained release excipients include a release controlling excipient comprising an amphiphilic starch.
    Type: Application
    Filed: April 14, 2005
    Publication date: July 17, 2008
    Applicant: VECTURE LIMITED
    Inventors: John Staniforth, Naresh Talwar
  • Publication number: 20060099245
    Abstract: The present invention relates to an oral drug delivery system with biphasic release characteristics comprising a porous matrix comprising at least one drug substance, sugar(s), a release retarding polymer, gas generating components and optionally, pharma-ceuti-cally acceptable auxiliary components wherein the pharmaceutical composition further comprises a coating of said drug substance. The pharmaceutical composi-tion, either in the form of pellets (multiparticulate or single unit dosage form), beads, granules, capsules or tablets, is retained in the stomach while selectively delivering the drug(s) at gastrointestinal levels and upper parts of the small intestine over an extended period of time. The release of the drug from the said pharmaceutical composition is characterized by a biphasic release profile of the drug substance, which exhibits both immediate and controlled release characteristics.
    Type: Application
    Filed: May 21, 2002
    Publication date: May 11, 2006
    Inventors: Manoj Kumar, Naresh Talwar, Rajeev Raghuvanshi, Ashok Rampal
  • Patent number: 6960356
    Abstract: A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% profloxacin base, 0.34% sodium alginate, 1.103% xanthan gum, 13.
    Type: Grant
    Filed: July 2, 1999
    Date of Patent: November 1, 2005
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Naresh Talwar, Himadri Sen, John N. Staniforth
  • Publication number: 20050089572
    Abstract: The present invention relates to an oral drug delivery system comprising pravastatin or its pharmaceutically acceptable salts such that the system provides enhanced stability in the acidic environment of the stomach and exhibits controlled release of the drug.
    Type: Application
    Filed: March 22, 2002
    Publication date: April 28, 2005
    Inventors: Manoj Kumar, Naresh Talwar, Rajeev Raghuvanshi, Ashok Rampal
  • Patent number: 6261601
    Abstract: A pharmaceutical composition in the form of tablets or capsules provides a combination of temporal and spatial control of drug delivery to a patient for effective therapeutic results. The pharmaceutical composition comprises a drug, a gas generating component, a swelling agent, a viscolyzing agent, and optionally a gel forming polymer. The swelling agent belongs to a class of compounds known as superdisintegrants (e.g., cross-linked polyvinylpyrrolidone or sodium carboxymethylcellulose). The viscolyzing agent initially and the gel forming polymer thereafter form a hydrated gel matrix which entraps the gas, causing the tablet or capsule to be retained in the stomach or upper part of the small intestine (spatial control). At the same time, the hydrated gel matrix creates a tortuous diffusion path for the drug, resulting in sustained release of the drug (temporal control). A preferred once daily ciprofloxacin formulation comprises 69.9% ciprofloxacin base, 0.34% sodium alginate, 1.03% xanthan gum, 13.
    Type: Grant
    Filed: September 14, 1998
    Date of Patent: July 17, 2001
    Assignee: Ranbaxy Laboratories Limited
    Inventors: Naresh Talwar, Himadri Sen, John N. Staniforth